PVT1 and urinary bladder carcinoma: Another study indicated that PVT1 promotes the expression of MDR1 and MRP1 in bladder cancer by activating the Wnt/β-catenin pathway, ultimately reducing the response of bladder cancer cells to doxorubicin and cisplatin (Fig. 6G) [187].